
Zealand Pharma A/S
OTC:ZLDPF


to continue ZLDPF research
to continue ZLDPF research
You've reached your weekly stock limit.
Sign UpZealand Pharma A/S?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
57.225
141.742
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Zealand Pharma A/S hold over its rivals?
What risks and challenges
does Zealand Pharma A/S face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Zealand Pharma A/S.
Provide an overview of the primary business activities
of Zealand Pharma A/S.
What unique competitive advantages
does Zealand Pharma A/S hold over its rivals?
What risks and challenges
does Zealand Pharma A/S face in the near future?
Summarize the latest earnings call
of Zealand Pharma A/S.
What significant events have occurred
in Zealand Pharma A/S over the past months?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Zealand Pharma A/S.
Provide P/S
for Zealand Pharma A/S.
Provide P/E
for Zealand Pharma A/S.
Provide P/OCF
for Zealand Pharma A/S.
Provide P/FCFE
for Zealand Pharma A/S.
Provide P/B
for Zealand Pharma A/S.
Provide EV/S
for Zealand Pharma A/S.
Provide EV/GP
for Zealand Pharma A/S.
Provide EV/EBITDA
for Zealand Pharma A/S.
Provide EV/EBIT
for Zealand Pharma A/S.
Provide EV/OCF
for Zealand Pharma A/S.
Provide EV/FCFF
for Zealand Pharma A/S.
Provide EV/IC
for Zealand Pharma A/S.
Show me price targets
for Zealand Pharma A/S made by professional analysts.
What are the Revenue projections
for Zealand Pharma A/S?
How accurate were the past Revenue estimates
for Zealand Pharma A/S?
What are the Net Income projections
for Zealand Pharma A/S?
How accurate were the past Net Income estimates
for Zealand Pharma A/S?
What are the EPS projections
for Zealand Pharma A/S?
How accurate were the past EPS estimates
for Zealand Pharma A/S?
What are the EBIT projections
for Zealand Pharma A/S?
How accurate were the past EBIT estimates
for Zealand Pharma A/S?
Compare the revenue forecasts
for Zealand Pharma A/S with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Zealand Pharma A/S and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Zealand Pharma A/S against its competitors.
Analyze the profit margins
(gross, operating, and net) of Zealand Pharma A/S compared to its peers.
Compare the P/E ratios
of Zealand Pharma A/S against its peers.
Discuss the investment returns and shareholder value creation
comparing Zealand Pharma A/S with its peers.
Analyze the financial leverage
of Zealand Pharma A/S compared to its main competitors.
Show all profitability ratios
for Zealand Pharma A/S.
Provide ROE
for Zealand Pharma A/S.
Provide ROA
for Zealand Pharma A/S.
Provide ROIC
for Zealand Pharma A/S.
Provide ROCE
for Zealand Pharma A/S.
Provide Gross Margin
for Zealand Pharma A/S.
Provide Operating Margin
for Zealand Pharma A/S.
Provide Net Margin
for Zealand Pharma A/S.
Provide FCF Margin
for Zealand Pharma A/S.
Show all solvency ratios
for Zealand Pharma A/S.
Provide D/E Ratio
for Zealand Pharma A/S.
Provide D/A Ratio
for Zealand Pharma A/S.
Provide Interest Coverage Ratio
for Zealand Pharma A/S.
Provide Altman Z-Score Ratio
for Zealand Pharma A/S.
Provide Quick Ratio
for Zealand Pharma A/S.
Provide Current Ratio
for Zealand Pharma A/S.
Provide Cash Ratio
for Zealand Pharma A/S.
What is the historical Revenue growth
over the last 5 years for Zealand Pharma A/S?
What is the historical Net Income growth
over the last 5 years for Zealand Pharma A/S?
What is the current Free Cash Flow
of Zealand Pharma A/S?
Discuss the annual earnings per share (EPS)
trend over the past five years for Zealand Pharma A/S.
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
DK |
![]() |
Zealand Pharma A/S
OTC:ZLDPF
|
25.9B USD | -12.7 | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD | -195 193 |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
324.6B USD | 22.1 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
146.5B USD | 22.3 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
132.2B USD | 13.3 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114B USD | 25.6 |
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -556.9 |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
117B AUD | 21.3 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.4B USD | 12.2 |
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -59.2 |
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.8B USD | -339.7 |
|
EBIT Growth | EV/EBIT to Growth | |||||
---|---|---|---|---|---|---|
DK |
![]() |
Zealand Pharma A/S
OTC:ZLDPF
|
Average EV/EBIT:
19.5
|
N/A | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
Negative Multiple: -195 193 | N/A | N/A |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
22.1
|
29%
|
0.8 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
22.3
|
32%
|
0.7 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
13.3
|
11%
|
1.2 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
25.6
|
17%
|
1.5 |
|
US |
E
|
Epizyme Inc
F:EPE
|
Negative Multiple: -556.9 | N/A | N/A |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
21.3
|
14%
|
1.5 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
12.2
|
11%
|
1.1 |
|
US |
S
|
Seagen Inc
F:SGT
|
Negative Multiple: -59.2 | N/A | N/A |
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Negative Multiple: -339.7 | N/A | N/A |
|
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.